George Scangos, Biogen

CEO, Biogen
Total 2014 Compensation: $18.63 million

Biogen ($BIIB) has been on a growth streak, fueled by its multiple sclerosis hotshot pill Tecfidera. It recently rolled out two next-gen hemophilia drugs. And it has whetted investors' appetite with early-stage results for an Alzheimer's drug that--if successful, and that's a big if--could zoom to $5 billion in peak sales. The company is so jazzed about its pipeline that it's building a $1 billion plant in Switzerland and figures it will need more manufacturing capacity to keep up.

CEO George Scangos has watched his pay grow, too. Scangos totted up $18.6 million for 2014, up from $15 million in 2013 and $13.45 million the year before that.

Scangos' compensation is heavily weighted toward equity, but he has collected sizable cash incentive pay, too. His base salary was a run-of-the-mill $1.38 million for 2014--on par with that of many other biopharma chiefs--but his incentive pay was on the higher end of things at $4.05 million.

Perhaps that's because Biogen doesn't hand out options. Scangos' equity compensation was all on the stock-award side at $12.12 million. $90,000 in pension benefits and $1 million in other compensation round out the total.

For more:
Special Reports: 15 Highest-Paid Biopharma CEOs of 2013 - George Scangos, Biogen Idec | The 25 most influential people in biopharma today - George Scangos
Biogen to build $1B plant, add 400 jobs in Switzerland
Which Big Biotechs join Gilead in Fortune's fastest-growing pharma ranks?
Biogen's hot MS meds could push Pfizer off its CNS throne
Back-to-'Biogen' shift signals wider industry branding trend
Move over, Big Pharma: Smaller biopharma's execs are bringing home more bacon

George Scangos, Biogen

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.